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In this double-blind, placebo-controlled
study, 363 patients with untreated multiple
myeloma were randomized to receive either
melphalan-prednisone and thalidomide
(MPT) or melphalan-prednisone and pla-
cebo (MP). The dose of melphalan was
0.25 mg/kg and prednisone was 100 mg
given daily for 4 days every 6 weeks until
plateau phase. The dose of thalidomide/
placebo was escalated to 400 mg daily until
plateau phase and thereafter reduced to
200 mg daily until progression. A total of
357 patients were analyzed. Partial re-
sponse was 34% and 33%, and very good
partial response or better was 23% and 7%
in the MPT and MP arms, respectively
(P< .001). There was no significant differ-
ence in progression-free or overall survival,
with median survival being 29 months in the
MPT arm and 32 months in the MP arm.
Most quality of life outcomes improved
equally in both arms, apart from constipa-
tion, which was markedly increased in the
MPT arm. Constipation, neuropathy, non-
neuropathy neurologic toxicity, and skin re-
actions were significantly more frequent in
the MPT arm. The number of thromboem-
bolic events was equal in the 2 treatment
arms. In conclusion, MPT had a significant
antimyeloma effect, but this did not trans-
late into improved survival. This trial was
registered at www.clinicaltrials.gov as
#NCT00218855. (Blood. 2010;116(9):
1405-1412)
Introduction
In recent years, there has been considerable progress in the
treatment of multiple myeloma. Thalidomide was demonstrated to
be effective in patients with relapsing multiple myeloma in 1999.1
This discovery generated an array of studies that confirmed the
initial results that approximately 30% of patients with relapsing
multiple myeloma respond to thalidomide.2 A further step was to
test the effect of thalidomide in newly diagnosed multiple my-
eloma; and in 2000 to 2001, several groups in Europe launched
randomized studies with similar design, aimed at patients who had
not received previous treatment and were not eligible for high-dose
therapy. An Italian randomized study with melphalan, prednisone,
and thalidomide (MPT) versus melphalan and prednisone (MP)
demonstrated a significant difference in progression-free survival
(PFS),3 but this did not translate into an overall survival (OS)
benefit.4 A French study demonstrated a significant difference in
both PFS and OS in patients 65 to 75 years of age,5 and the same
result was found in a separate study in patients older than 75 years.6
A Dutch study has demonstrated a difference in event-free survival
but no difference in OS.7
In the Nordic countries, we started a phase III trial in 2002 in
which 363 patients not eligible for high-dose treatment with stem
cell support were randomized to receive either MPT or MP and
placebo. In this report, we present the results of this study.
Methods
Patients
Criteria of inclusion in the study included previously untreated symptom-
atic multiple myeloma in patients who were not eligible for high-dose
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treatment with autologous stem cell support. A diagnosis of multiple
myeloma was based on these criteria: criterion A (monoclonal Ig  30 g/L
or IgA  20 g/L, IgD, or IgE of any concentration in serum and/or - or
-light chain  1 g/24 hours in urine); criterion B (M protein at a lower
concentration than in criterion A); criterion C (10% or more of plasma cells
in the bone marrow or a plasma cell tumor in bone or soft tissue); and
criterion D (osteolytic destructions in the skeleton). To make a diagnosis of
multiple myeloma, the combination of A  C, A  D, B  C  D or, in
case of nonsecretory multiple myeloma, C  D was required. Durie-
Salmon stage I to III and performance status World Health Organization
(WHO) 0 to 4 were accepted.
Women of childbearing age, patients with psychiatric disease, and those
expected to survive less than 3 months were excluded, as were patients who did
not cooperate or who refused consent. Patients were recruited from 48 hospitals
in Norway, Sweden, and Denmark from January 2002 to May 2007.
Study design
Patients were randomized to receive either MPT or MP with placebo.
Randomization was centralized and performed by telephone call or fax. The
randomization was stratified according to WHO performance status ( 2 or
3-4) and 2-microglobulin ( 2.6 mg/L,  2.6 mg/L, or not known). The
primary endpoint of the study was OS. Secondary endpoints were PFS,
response rate, time to progression health-related quality of life, and toxicity.
All patients gave written informed consent in accordance with the
Declaration of Helsinki. The study was approved by ethics committees and
authorities in Norway, Sweden, and Denmark. All authors had access to
primary clinical trial data.
A safety committee with 3 independent members evaluated the study
when 150 patients had been observed for 6 months. Results and toxicity
were found acceptable by the committee. The study was unblinded in
November 2007. The evaluation of outcomes was performed without
knowledge of treatment arm.
The dose of melphalan was 0.25 mg/kg, and the dose of prednisone was
100 mg daily for 4 days every 6 weeks. Cycles of treatment were continued
until plateau phase. The dose of thalidomide/placebo was 200 mg daily for
one week and thereafter 400 mg daily. This dose was maintained until
plateau phase and thereafter continued at 200 mg daily. Dose reduction was
allowed if necessary because of side effects. The study drug was stopped,
and further treatment was decided by the investigator in the event of
primary resistance, intolerable side effects, or withdrawal of consent. The
recommendation in the protocol was to repeat the induction treatment at
first relapse and continue maintenance treatment until second relapse.
However, most investigators stopped the study drug at first relapse. No
routine prophylaxis for venous thrombosis was recommended. Thalidomide
and placebo were provided by Gru¨nenthal and stored in a central pharmacy
in each of the countries. The content of thalidomide in the tablets was
assayed twice during the study and was found to be unchanged (97.5-
99.5 mg thalidomide per tablet; DB Lab). Melphalan and prednisone were
ordered from the pharmacies as standard treatment. Whether thalidomide or
placebo was given was unknown to the patient, investigator, and monitor.
Response and relapse were evaluated by the investigator and reevaluated by
the working group for the study in several meetings.
Laboratory investigations included hemoglobin, white blood cell count,
platelets, creatinine, calcium, albumin, alanine aspartate transaminase, and
prothrombin time-international normalized ratio. Patients were monitored
with blood samples, clinical evaluation, and response evaluation every
6 weeks during the first 6 months, and thereafter every third month. Bone
marrow aspirate was taken at diagnosis and thereafter on demand or to
confirm a complete remission.
Health-related quality of life was measured by the validated European
Organization of Research and Treatment of Cancer QLQ-C30 question-
naire, which was completed by the patient at inclusion and later posted to
the patient every third month throughout the study.
In 2006, it was decided to send out a questionnaire for 328 patients to all
investigators asking whether thromboembolic events had been observed. It
was also asked whether and for which time periods the patients were using
warfarin, heparin, salicylates, or erythropoietin.
Definitions
Partial response (PR) was defined as more than 49% reduction of M protein
in serum and more than 89% reduction of M protein in urine or to a level of
less than 0.2 g/24 hours. In addition, a more than 49% reduction of size of
soft tissue plasmacytoma and no increase of size or number of bone lesions
was required for PR. If a reduction of M protein was difficult to observe
because of low initial concentration, a reduction in the number of plasma
cells in a bone marrow smear could be used. Very good partial remission
(VGPR) was defined as more than 89% reduction of M protein in serum and
in urine to less than 100 mg/24 hours. Complete response (CR) was defined
as no detectable M protein in serum or urine as assayed by electrophoresis,
less than 5% plasma cells in bone marrow, total regression of soft tissue
plasmacytoma, and no increase in size and number of bone lesions.
Immunofixation was not required. Minor response (MR) was defined as
25% to 49% reduction of M protein in serum and a 50% to 89% reduction of
M protein in urine, but not to a level of less than 0.2 g/24 hours. In addition,
a 25% to 49% reduction of size of soft tissue plasmacytoma and no increase
in size or number of bone lesions were required for MR. For all categories
of response, we considered that new vertebral compression fractures did not
exclude response. Responders had to show clinical improvement, no need
of transfusions, normal serum calcium, and no increase of creatinine.
Nonresponse (NR) was defined as not meeting the criteria for CR, PR, MR,
or PD. The best response during the first 12 months was recorded.
Plateau phase was defined in patients achieving CR, PR, or MR as either
no detectable M protein or less than 10% variation in 3 consecutive analyses
of M protein in serum, or 3 analyses of M protein in urine with values less
than or equal to 0.2 g/24 hours. After response, progressive disease (PD)
was defined as at least 2 consecutive analyses (first taken as date of relapse)
with an increase in M protein in serum of more than 24% (to at least 10 g/L)
or an increase in M protein in urine of more than 24% (to at least 1 g/24
hours), or any other unequivocal sign of disease progression (hypercalce-
mia, increase of osteolytic foci or plasmacytoma, or increase in number of
plasma cells in the bone marrow). A similar definition was used for
progression from NR. In addition, patients with NR or MR were recorded as
having PD when new treatment was started, irrespective of concentration of
M protein.
PFS was calculated from the date of randomization until the date of
progress/relapse or death of any cause. Time to progression was calculated
from the date of randomization until progression/relapse.
Statistical analysis
The sample size needed to detect a hazard ratio of 1.4 was calculated; this
corresponds to anticipated median survival of 28 months (MP) versus
40 months (MPT). For 80% power and a type I error of 5%, 282 events
(deaths) are required. Thus, it was planned to recruit 800 patients (400 in
each group), with analyses taking place at 40 months after trial initiation.
In the event, fewer patients were recruited (175 MP, 182 MPT). By
December 2008, 209 deaths had occurred, whereas we estimated 282 in the
protocol. This means that the effective power is reduced to 72% or,
equivalently, that we have 80% power of detecting a hazard ratio of 1.48
instead of 1.4 as specified in the design. For PFS, 272 events were observed,
providing 79% power to detect a ratio of 1.4
Survival curves were consistent with proportional hazards, and so Cox
models were used on an intention-to-treat basis with covariate adjustment
considered for stage of disease, performance status, age, and sex. The
results of these analyses were confirmed using log-rank tests.
The patients’ self-assessments of quality of life using the QLQ-C30
were analyzed using standardized area under the curve. Generalized
estimating equations were also used; these make full use of the repeated
quarterly (every 3 months) measures and allow for the within-patient
correlations over successive time points. Analyses were carried out first
using the observed values of the QLQ-C30 scores, and then with baseline
(prerandomization) QLQ-C30 scores as covariates; this second analysis is
equivalent to examining change from baseline for each patient. Physical
functioning, from the QLQ-C30, was prespecified in the protocol as being
the primary health-related quality of life outcome of interest. The random-
ization stratification factors (WHO and 2-microglobulin) were also used as
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covariates, together with baseline characteristics (International Staging
System [ISS], age, and sex) when they were found to be significant
prognostic indicators of outcome. Because the results were in all cases
similar, only the analyses adjusted for baseline QLQ-C30 score are
presented. To further investigate the impact of potential bias from missing
data, multiple imputation was explored using the ICE and MIM programs
and predictive factors.8,9
All analyses were carried out using STATA version 10.0 (Stata
Statistical Software, Release 10, StataCorp LP).
Results
A total of 363 patients were included and randomized. Six patients
were excluded from analysis as shown in Figure 1; 2 withdrew
consent before treatment, and 6 were lost to follow-up. In addition,
one duplicate randomization was excluded. A total of 357 patients
were analyzed: 182 patients in the MPT arm and 175 patients in the
MP arm (Figure 1). Among these, 25 patients were not evaluable
for response in the MPT arm and 13 patients in the MP arm because
of early exclusion (4 MPT, 3 MP), early death (12 MPT, 8 MP), and
missing follow-up data (9 MPT, 2 MP). These patients were
included in the survival. Information about length of treatment and
discontinuation is given in Figure 1. Baseline characteristics of the
patients are shown in Table 1.
All patients were followed up with respect to response and
toxicity until November 2007 (6 months after the last inclusion),
and 18 additional months for survival (ie, until December 2008).
The median follow-up time, defined as time from randomization to
last follow-up with censoring for death, was 42 months.
Survival
OS is shown in Figure 2, and there is no statistically significant
difference (P  .16, Cox model with covariates, P  .35, log-rank
test ignoring covariates). Median survival was 29 months
(95% confidence interval [CI], 25-38 months) in the MPT arm
and 32 months (95% CI, 27-38 months) in the MP arm. There
was no difference in PFS between the 2 arms (Figure 3), with
medians of 15 months (95% CI, 12-19 months) for MPT and
14 months (95% CI, 11-18 months) for MP. In those with
reported progression, the median time to progression was
13 months (95% CI, 11-15 months) in the MPT arm and
12 months (95% CI, 10-14 months) in the MP arm (P  .84,
log-rank test) (data not shown).
Inspection of the survival curves suggested a slight increase in
mortality in the thalidomide arm during the first 6 months. In this
period, there were 35 deaths in the MPT arm versus 21 deaths in the
363 patients randomly assigned 
1 withdrawal of consent 
1 randomized twice 
1 did not fulfill inclusion criteria 
1 no information 
179 patients allocated to MP + placebo 184 patients allocated to MPT 
1 withdrawal of consent 
1 no information 
3 did not start treatment 
179 patients analyzed for toxicity
182 patients analyzed  for survival 
88 patients used thalidomide until PD, MR, NR, 
death or date of last contact 
79 patients prematurely discontinued 
thalidomide 
 59 patients due to toxicity 
 12 patients other causes 
  4 patient wish 
  3 never started 
  5 lack of compliance 
   8 unknown cause 
15 patients no information 
84 patients had PD 
109 patients died 
3 did not start treatment 
172 patients analyzed for toxicity 
175 patients analyzed for survival 
130 patients used placebo until PD, MR, NR, 
death or date of last contact 
35 patients prematurely discontinued placebo 
 18 patients due to toxicity 
 10 patients other causes 
  2 patient wish 
  3 never started 
  3 lack of compliance 
  2 unconfirmed PD 
   7 unknown cause 
10 patients no information  
105 patients had PD 
100 patients died 
Figure 1. Overview of patients randomized, excluded, and analyzed.
Table 1. Baseline characteristics of patients
Characteristic MPT (n  182) MP (n  175)
Age, y
Median 74.6 74.1
Younger than 65, no. (%) 3 (2) 3 (2)
65-69, no. (%) 34 (19) 36 (21)
70-74, no. (%) 62 (34) 56 (32)
75-79, no. (%) 45 (25) 38 (22)
Older than 79, no. (%) 38 (21) 42 (24)
Male sex, % 51 61
Durie-Salmon stage, %
I 12 18
II 41 31
III 43 46
Missing 4 5
ISS stage, %
1 13 18
2 37 43
3 36 30
Missing 14 9
WHO performance status, %
0-2 67 65
3-4 27 33
Missing 5 3
Median 2-microglobulin, mg/L
(25%-75% range)
4.5 (3.1-8.8) 4.2 (3.1-6.4)
Median hemoglobin, g/dL
(25%-75% range)
10.3 (9.3-11.8) 10.8 (9.7-11.8)
Median creatinine, M
(25%-75% range)
95 (77-131) 94 (79-135)
Median calcium, mM
(25%-75% range)
2.5 (2.4-2.7) 2.5 (2.4-2.6)
0.
0
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173 131 87 50 26 MP
181 130 84 48 23   MPT
Number at risk
0 12 24 36 48
months
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Overall survival, by treatment
Figure 2. OS.
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MP arm; however, even ignoring the fact that this was a post hoc
analysis, this difference is not statistically significant. By further
analyses, it was observed that the increase in deaths was mainly
among patients older than 75 years (Figure 4). In this group,
23 died in the MPT arm and 12 died in the MP arm. Below 75 years
of age, the corresponding figures were 12 and 9 deaths. We
classified the cause of death without knowing the treatment
allocation. Above 75 years of age, 8 patients died from infection,
6 died of unknown cause (no information, uncertain classification),
and 6 died of progressive disease in the MPT arm, whereas the
corresponding numbers in the MP arm were 3, 1, and 4 patients.
There was no evidence of age (older/younger than 75 years)
interaction on PFS (P  .31), on OS (P  .92), or on time to
progression (P  .75). Similar results were observed for ISS and
2-microglobulin.
Response rates
Best responses obtained in the first 12 months are shown in Table 2.
In the MPT group, 57% had at least PR and 23% had at least
VGPR, whereas the corresponding number was 40% and 7% in the
MP group (2 for trend, P 	 .001).
Quality of life
Compliance with completing the QLQ-C30 was 82% in the MPT
arm and 90% in the MP arm at 3 months and 50% and 62%,
respectively, at 12 months. Figure 5 shows the mean QLQ-C30
scores only for those patients who returned completed question-
naires. In both treatment arms, the quality of life improved after
initiation of treatment. There was a marked increase in constipation
among patients in the MPT arm (P 	 .001, analyses by generalized
estimating equations), with a corresponding slight tendency to
diarrhea in the MP patients (P  .002). There were borderline
significant differences in physical function (P  .025) and social
function (P  .013). Comparable results were obtained from
analyses using standardized area under the curve, confirming
the robustness of the analyses. In an attempt to check whether there
was probably bias arising because of the poor compliance, the
analyses were repeated using multiple imputation; the revised
P values were .001 (constipation), .033 (diarrhea), .14 (physical
function), and .024 (social function).
Dose of thalidomide
The actual dose of thalidomide and placebo taken at day 30, day 90,
and at one year is given in Table 3. The intended dose was 400 mg
for patients before plateau phase and 200 mg after plateau phase
had been reached. Both these categories of patients are included in
the table. The calculations demonstrate that an increased number of
patients had to discontinue thalidomide, as well as a marked
reduction in actual dose of thalidomide taken. We analyzed the
doses taken according to age and did not find any indication that
patients older than 75 years took lower doses or stopped taking
thalidomide compared with patients younger than 75 years (data
not shown). Median duration of thalidomide treatment for patients
living longer than one year was 236 days.
Relapse treatment
The choice of therapy after relapse is known for 71 of 82 (87%)
patients in the MPT arm and 87 of 104 (84%) in the MP arm (Table
4). A total of 45% of the patients in the MP arm received
thalidomide-based chemotherapy at first relapse or later, whereas
the corresponding number was 23% in the MPT arm. Bortezomib
was given to 18% and 20% and lenalidomide to 3% and 2% in the
MP and MPT arms, respectively.
Toxicity
The adverse events that were significantly more frequent in the
MPT arm are shown in Table 5. In addition, somnolence/fatigue
was more frequent in the MPT arm, however, with borderline
significance (30% grade 1 or 2, 8% grade 3 or 4 vs 26% and
4% in the placebo group, P  .080). The incidence of grade 3 or
4 toxicity for hemoglobin levels was 4% versus 8%, for
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Number at risk
0 12 24 36 48
months
MP
Progression-free survival
MPT
Figure 3. PFS.
Figure 4. OS in different age groups.
Table 2. Best response to treatment in first 12 months
MPT, n (%) MP, n (%)
CR 23 (13) 7 (4)
VGPR 18 (10) 6 (3)
PR 63 (34) 57 (33)
MR 26 (14) 45 (26)
NR 27 (15) 47 (27)
NE 25 (14) 13 (7)
2 for trend, P 	 .001.
NE indicates not evaluable.
1408 WAAGE et al BLOOD, 2 SEPTEMBER 2010  VOLUME 116, NUMBER 9
For personal use only.on January 15, 2017. by guest  www.bloodjournal.orgFrom 
granulocytes 25% versus 20%, for platelets 8% versus 11%, for
infections 15% versus 10%, and for cardiologic toxicity 7% ver-
sus 5% in the MPT arm versus the MP arm. The differences were
not statistically significant. There were equal numbers of cardiac
infarction and heart insufficiency in both arms.
A total of 59 patients discontinued thalidomide resulting from
toxicity, whereas 18 patients discontinued in the placebo group
(Figure 1). The side effects that most frequently led to discontinua-
tion of thalidomide were polyneuropathy in 13 patients, constipa-
tion in 8 patients, skin reactions in 7 patients, somnolence in
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Figure 5. Self-reported quality of life during 36 months. (A) Global parameters. (B) Specific health parameters. Data are mean values and 95% confidence intervals. QL
indicates global quality of life; RF, role function; PF, physical function; SF, social function; EF, emotional function; CF, cognitive function; DI, diarrhea; CO, constipation; AP,
appetite loss; NV, nausea/vomiting; DY, dyspnea; SL, sleep loss; PA, pain; FA, fatigue; and FI, financial problems.
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7 patients, and dizziness in 6 patients (included in nonneuropathy
neurologic toxicity). The corresponding number of patients in the
MP arm were 0, 1, 0, 0, and 2.
Thromboembolic events
The incidence of thromboembolic events was analyzed both by
ordinary case report forms and by a separate questionnaire. The
investigators responded to the questionnaire from 243 (75%)
patients: 123 in the MPT arm and 120 in the MP arm. The number
of patients with thromboembolic events was altogether 15 (8%) in
the MPT arm and 14 (8%) in the MP arm. Of these, 12 patients were
spontaneously reported in the MPT arm and 7 patients in the MP
arm. It was altogether registered 14 patients with deep vein
thrombosis (DVT), 14 patients with pulmonary embolism, and one
patient with both. Median time to the thromboembolic event was
64 days (range, 3-1509 days) in the MPT arm and 280 days (range,
0-743 days) in the MP arm (not significant). No antithrombotic
prophylaxis was recommended in the study.
By the questionnaire, we also obtained information of the
number of patients using anticoagulants for other reasons or
erythropoietin. Salicylates were used by 24% and 23% and
warfarin was used by 15% and 17% in the MPT and MP arms,
respectively. Altogether, 39% and 40% of the patients in the
2 treatment arms used drugs that may have prophylactic effect on
thromboembolic events. Erythropoietin was used by 11% in the
MPT arm and 16% in the MP arm (not significant).
Discussion
In this randomized, placebo-controlled study, we found that
addition of thalidomide to standard MP therapy in elderly myeloma
patients had a significant antimyeloma effect in terms of increased
proportions of high-quality responses. Despite this, we found no
significant impact on PFS or OS.
The optimal dose of thalidomide is not established. In the
studies that introduced thalidomide in relapsing myeloma, the
intended dose was 800 mg, which later was shown to be too high a
dose.1 In the present study, we aimed at a dose of 400 mg in the
treatment phase and 200 mg in the maintenance phase. However,
during the course of the study, there was an increasing understand-
ing that lower dose was sufficient for optimal effect. In addition, the
potency of thalidomide became more evident in terms of side
effects; and as a consequence, the actual dose taken tended to be
reduced. By 3 months, fewer than 20% of patients were taking
400 mg of thalidomide, and 28% had stopped treatment. This dose
was calculated from patients with active treatment (planned dose,
400 mg) as well as from patients in maintenance phase (planned
dose, 200 mg). In the MP arm, the corresponding percentages were
50% and 12%, confirming the need for considerable dose reduction
in the thalidomide arm.
MPT has been compared with MP in 5 randomized trials: an
Italian study,3 2 French studies in patients younger than 75 years5
and patients 75 years of age and older,6 a Dutch study,7 and the
present Nordic study. All studies have reported significant improve-
ment of response rate by the addition of thalidomide. However,
there are differences regarding impact on survival. In the 2 French
and the Dutch studies, OS and PFS were significantly increased. In
the Italian study, PFS or event-free survival, but not OS, was
significantly improved. In the Nordic study, neither PFS nor OS
was improved.
Certain aspects that may have significance for the differences
between the studies are discussed here. There were differences in
inclusion criteria between the studies, which was reflected in
particular by the fact that 30% of the patients in our study had
WHO performance status 3 or 4 compared with 6% to 8% and 6%
in the Italian3 and French5,6 studies. The proportion of patients with
WHO performance status more than 3 in our study is similar to our
earlier population-based, unselected, and nearly complete registra-
tion studies.10
In addition, the scheduled dose of melphalan and thalidomide
varied considerably between the studies. However, none of the
studies was designed for evaluating optimal dose of thalidomide,
and it is difficult to draw detailed conclusions about dose or
duration of treatment and effect across the studies. We notice that
beneficial effect has been observed at a dose of 100 mg daily,
indicating that a dose in the lower range is sufficient
The median age in all studies was quite similar, ranging from
70 to 74 years in 4 of the studies.3,5,7 Age alone is therefore
probably not of major importance. This is further underlined by the
French study on patients older than 75 years, which demonstrates a
survival benefit of thalidomide.6
In conclusion, patient selection and, in particular, differences in
proportion of WHO performance status more than 3, differences in
dose and schedule of thalidomide and melphalan may have impact
on the result. Comorbidity that is common in the older age groups
may influence the WHO performance status. One might speculate
whether high doses of thalidomide and inclusion of patients with
Table 4. Relapse treatment in patients with progressive disease
MPT (N  82), n (%) MP (N  104), n (%)
Thalidomide 23 (28) 47 (45)
Bortezomib 16 (20) 19 (18)
Lenalidomide 2 (2) 3 (3)
Cyclophosphamide 20 (24) 18 (17)
MP 34 (41) 31 (30)
MPT/placebo 3 (4) 4 (4)
Steroids/VAD 7 (9) 10 (10)
Other 3 (4) 2 (2)
No treatment 7 (9) 8 (8)
No information 11 (13) 17 (16)
VAD indicates vincristin, adriamycine, dexamethasone.
Table 3. Percentage of patients continuing to take none, 200 mg, or 400 mg of thalidomide or placebo
30 days 90 days 1 year
MPT, percentage MP, percentage MPT, percentage MP, percentage MPT, percentage MP, percentage
Stopped therapy 22 9 32 11 56 33
Less than 200 mg 8 5 12 5 12 6
200 mg 41 44 33 30 25 39
400 mg 29 42 23 54 7 22
No. of patients evaluated 170 167 152 156 109 100
Patients who died or relapsed before the indicated time point are excluded from the analysis.
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poor performance status may at least to some extent explain the
lack of translation from good responses to improved PFS or OS in
our study.
We noted in a retrospective analysis that there was an increased
number of deaths in the early phase of thalidomide treatment in
patients older than 75 years. It is of interest that a similar increase
of early deaths was observed in the Italian study3 and Dutch study7
as well as in a study comparing thalidomide-dexamethasone with
MP.11 The early phase of treatment appears to be vulnerable, and
selection of patients to receive thalidomide may be of importance.
A practical conclusion is to use thalidomide at doses of 100 to
200 mg and exclude patients or reduce dose in patients with age
older than 75 years and WHO performance status 3 or 4.
Thalidomide plus dexamethasone has also been evaluated in
phase III clinical trials.11-13 Thalidomide plus dexamethasone
produced better responses compared with dexamethasone12,13 or
MP,11 whereas survival was reduced compared with MP.11 In the
studies comparing thalidomide plus dexamethasone with dexameth-
asone alone, there was improvement in time to progression and
PFS,12 but not in OS.12,13 However, these studies were not powered
to detect differences in survival.
The proportions of patients who discontinued thalidomide
increased gradually from 22% at one month to 56% at one year.
However, the specific thalidomide-related discontinuation was
lower as 9% and 33% of the patients discontinued the placebo drug
at the corresponding time points. Patients who had died or relapsed
were excluded from this analysis (ie, only patients expected to be
taking the study drug or placebo were evaluated). The discontinua-
tion of the drug was therefore assumed to be related to thalidomide
side effects or suspicion of this. Evaluation of the dose taken
demonstrates that the 400-mg dose of thalidomide was most often
reduced compared with placebo. Discontinuation of treatment
resulting from toxicity has been reported to be 31.6% after a
median of 2.2 months in the Italian study and 45% and 42% in the
2 French studies. In the Dutch study, only 28% received the full
dose of thalidomide after 6 cycles. All studies demonstrate that a
considerable proportion of patients have to stop treatment with
thalidomide. However, many patients taking placebo also discon-
tinue treatment. Our study specifically demonstrates a poor compli-
ance for the 400-mg dose of thalidomide.
We found significant differences in adverse events for neuropa-
thy, constipation, nonneuropathy neurologic toxicity, and exan-
thema and borderline significant difference for somnolence/fatigue.
Similar toxicity profile has also been reported by others. We notice
that our report differs somewhat from the French study, which also
was blinded.6 In this study, they observed significant difference for
neuropathy and grade 3 or 4 neutropenia, whereas we could not
confirm the latter.
During the study, it was reported by other investigators that there was
an increased incidence of DVT in patients taking MPT. We therefore
considered introducing prophylactic treatment for thromboembolism.
However, the total number of DVTs was low in our study, and we
explored this further by sending a questionnaire to all investigators in
2006. Surprisingly, the reported incidence of thromboembolic events
was 8% and equal in both treatment arms. Most studies on combination
treatment with thalidomide report an increased incidence of thromboem-
bolic events.14 In the Italian3 and French5 studies, thromboembolic
events were reported to be 20% and 12%, respectively, in patients not
receiving prophylaxis in the MPT arm. On the other hand, the
double-blind French study6 in older patients reports an overall incidence
of 7%; and similar to our study, there was no difference between the
treatment arms. Although no prophylaxis was recommended, we found
that 40% of the patients in our study were indeed taking drugs with
antithrombotic effect, and this may partially explain the low incidence of
thromboembolic events.
Quality of life is an important issue, particularly in the treatment
of an incurable disease. The use of the validated European
Organization of Research and Treatment of Cancer QLQ-C30
questionnaire sent directly to the patients every 3 months, together
with the placebo design of the study, allowed us to study quality of
life without any reporting bias. The QLQ-C30 measures both
global and more specific health parameters. An initial improved
quality of life was reported, reflecting response to treatment.
Although compliance in returning the questionnaires was poor after
the initial couple of assessments, later results were entirely
consistent with the (good compliance) patient reports at 3 and
6 months. Multiple imputation also showed no evidence that there
was bias in the comparison of treatments. We found a marked
difference in constipation between the 2 treatment arms and a
smaller but corresponding reverse effect on diarrhea, whereas there
were only minor differences in any other outcomes. A limitation of
the questionnaire is that it does not include specific questions
related to polyneuropathy, although this may partially have been
captured in the reported global quality of life. Investigator-reported
side effects and patient-reported quality of life are different and
complementary approaches to the problem of toxicity and tolerabil-
ity. Together, they provide a more complete insight into the impact
of thalidomide. It was interesting to note the discrepancy between
investigator- and patient-reported fatigue. Because fatigue is an
expected side effect of thalidomide, the physicians may have
overestimated it in patients who they suspected of being in the
thalidomide arm. Similarly, in unblinded trials, the side effects of
thalidomide may have been exaggerated.
A major strength of our study is the placebo-controlled design. The
study drug was blinded for the patients, the investigators, and the
monitors throughout the study until all decisions about response rates
and progression had been taken. This design protects against the
inevitable bias seen in open-labeled studies. It has been shown that
placebo-controlled studies generally find fewer and smaller differences
than open-labeled studies.15 However, the French study on patients older
than 74 years also had a blinded design and demonstrated a benefit for
thalidomide with respect to PFS and OS.6
Table 5. Reported toxicity that was significantly more frequent in the MPT group
Toxicity
Grade 1 or 2, no. (%) of patients Grade 3 or 4, no. (%) of patients
PMPT MP MPT MP
Constipation 66 (37) 47 (13) 11 (6) 5 (3) .003
Neuropathy 39 (21) 9 (6) 10 (6) 1 (1) .001
Nonneuropathy neurologic toxicity* 24 (14) 19 (11) 14 (8) 3 (2) .022
Exanthema 16 (9) 8 (4) 4 (2) 0 .019
Nonhematologic, altogether 84 (47) 54 (49) 70 (40) 33 (19) .001
*Includes tremor, ataxia, confusion, stroke, and dizziness.
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In conclusion, we report a significantly improved response rate
in previously untreated myeloma patients 65 years of age or older
by addition of thalidomide to standard MP. However, the study did
not confirm previous reports on improved PFS and OS. Patients
older than 75 years may be vulnerable in the initial phase of the
treatment, and further investigation of this group is indicated.
Meanwhile, care should be taken to avoid high doses of thalido-
mide to frail elderly patients.
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